TESARO, Inc. IPO Info

TESARO, Inc.

Company Name: TESARO, Inc.
Stock Symbol: TSRO
Exchange: NASDAQ
Status: Priced
IPO Date: 6/28/2012
IPO Price: 13.50 (24.81%)
Underwriters
Citigroup, Morgan Stanley, Leerink Swann, BMO Capital Markets, Baird

Amount of Offering: 103,500,000
Number of Shares Offered: 6 Mil
Shares Outstanding After Offering: 26.67 Mil
Valuation: 400,000,000.00
Company Description
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The company has in-licensed and is currently developing two product candidates, rolapitant and TSR-011.
  • Rolapitant, a potent and long-acting neurokinin-1, or NK-1, receptor antagonist currently in Phase 3 clinical trials for the prevention of chemotherapy induced nausea and vomiting, or CINV; and
  • SR-011, an orally available anaplastic lymphoma kinase, or ALK, inhibitor (targeted anti-cancer agent) currently in preclinical development. We plan to test TSR-011 in clinical trials as a treatment for non-small cell lung cancer, or NSCLC, and potentially other cancer indications.
Financial Data
The company has not posted revenues and lost $16.4 million in 2011.

SEC Filings

News Headlines